
****

**Draft** **Symposium programme:**

**“TB Vaccines: Global Collaboration and**

**Recent Advances in the Field”**

**Tuesday afternoon 29th January 2019**

**Programme**

*13.50 – 14.00 Photo whole group outside in front of the Maison des Congres*

14.00 - 14.05 Opening and Welcome - Nick Drager, TBVI, the Netherlands

***Global collaboration***

14.05-14.25 TBVAC2020: advances in the TB vaccine field - Ann Rawkins, PHE\_United Kingdom

14.25-14.45 BMGF TB vaccine programme – strategic directions and current activities – Willem Hanekom, BMGF, United States

14.45-15.05 Gates MRI Strategic Direction and Current TB Vaccine Activities - Penny Heaton GMRI, United States

15.05-15.25 NIAID strategic plan for TB research and current activities related to TB vaccines

Katrin Eichelberg, NIH, United States

15.25-15.45 Towards Horizon Europe – Hannu Laang, EC, Belgium

15.45-16.05 *speaker + title tbc*,IAS Global HIV Vaccine Enterprise

16.05-16.25 Future perspectives for TB vaccine development - Ole Olesen, EDCTP, The Netherlands

16.25-16.45 Introducing VALIDATE: A Global Challenges Research Fund network in vaccine R&D for complex intracellular pathogens, Helen McShane, UOXF, United Kingdom

16.45-17.15 *Coffee/Tea – Maison des Congres*

***TB treatment and vaccines***

17.15-17.35 Preferred product characteristics for a therapeutic TB vaccine – Barry Walker, TBVI, the Netherlands

***The TB vaccine pipeline***

17.35-17.50 Preferred Product Characteristics for a new TB vaccine –Johan Vekemans*,* WHO, Switzerland

17.50-18.10 TB vaccine pipeline and Pathway to TB vaccines – Georges Thiry, TBVI, the Netherlands

18.10 -18.30 Efficacy trials of M72/AS01E and H4/BCG revaccination - Key takeaways –

Ann Ginsberg- IAVI, United States

19.00 – 20.00 *Reception (Eurotel)*

20.00 *Dinner - Restaurant Eurotel*